BUYING GUIDE · GLOW BLEND · CANADA
How to Choose a Research-Grade GLOW Blend (BPC-157, TB-500, GHK-Cu) in Canada: A Supplier Checklist for Laboratories
Searches such as “GLOW blend Canada”, “GLOW peptide Canada”, “BPC-157 TB-500 GHK-Cu blend Canada” and “buy GLOW blend Canada” return listings that look nearly identical. A three-component blend is harder to evaluate than a single peptide, because every question you would ask about one molecule now applies three times, and new ones appear when the components share a vial. This guide is for laboratory researchers sourcing research-grade material in Canada. It sets out what to check before ordering and why, and it describes PurixLab’s GLOW BLEND 70mg as one option. It is a sourcing checklist for lab work, not guidance for human or veterinary use, and it makes no claims about what the blend or its components do.
What a GLOW blend is, in one paragraph
“GLOW” is a trade name rather than a defined chemical standard. It is generally used for a single vial combining BPC-157, TB-500 and the copper complex GHK-Cu. BPC-157 is a fifteen-residue peptide, GEPPPGKPADDAGLV, identified by doping-control chemists in confiscated vials [1]. TB-500 is a name used for a preparation built around a synthetic, N-terminally acetylated version of the thymosin beta-4 segment LKKTETQ [2,3]. GHK-Cu is the tripeptide glycyl-histidyl-lysine bound to copper(II) [4]. Because the name is not standardised, the first job is to establish what a given supplier actually means by it. Our GLOW BLEND research overview covers the background in more depth.
1. Get the composition in writing, component by component
Ask for the labelled amount of each component per vial, not only a total. Two products both sold as “70mg” could split that mass very differently, and the ratio decides how you design controls. Ask too whether each figure is net peptide content or the mass of powder weighed in. Synthetic peptides are usually isolated as salts, commonly trifluoroacetate from cleavage and purification, and the counter ion is hard to remove completely [5]. Counter ions and residual water add weight without adding peptide, so a gross figure and a net figure can differ noticeably for each component.
2. Confirm which TB-500 you are getting
This is the point most often skipped. Thymosin beta-4 is a 43-residue protein, and research has mapped activities to short regions within it, including the N-terminal Ac-SDKP tetrapeptide and the central actin-binding segment LKKTETQ [6]. Laboratories analysing a product sold as TB-500 identified the N-terminally acetylated 17-23 fragment, Ac-LKKTETQ, by high-resolution mass spectrometry [3], and a racing laboratory described the key ingredient of the veterinary preparation in the same way [2]. Some suppliers nonetheless use “TB-500” loosely for full-length thymosin beta-4. These are different molecules with very different masses. Ask which sequence is in the vial, whether the N-terminus is acetylated, and what the expected mass is.
3. Ask for identity data on all three components
Each component has a known sequence, so each can be identified by mass spectrometry. Published doping-control methods show that BPC-157 and the acetylated TB-500 fragment can be detected and distinguished by liquid chromatography-mass spectrometry, alongside their metabolites [1,2]. For a supplier the equivalent check is simpler: a mass spectrum, for the batch you will receive, showing an observed mass that matches the expected mass for each of the three components. Documentation that confirms one or two components and is silent on the third does not confirm the blend.
4. Treat a single purity percentage with caution
For one peptide, an HPLC purity figure describes the main peak as a share of the total. For a mixture of three, a single percentage is ambiguous: does it refer to one component, the sum of three main peaks, or each component tested before mixing? Ask for the chromatogram and the method, and ask whether the three components were tested individually before blending, as a finished blend, or both. Synthetic peptides carry predictable related impurities, such as deletion and insertion sequences, racemised residues, residual protecting groups, oxidised side chains and counter ions [7], and each component brings its own profile. A useful supplier answer names how the components and their main impurities were resolved from each other.
5. Ask about the copper
GHK-Cu is not simply a peptide: it is a metal complex. Solution studies found that copper(II) and GHK form multiple species depending on pH, including ternary complexes when another amino acid such as histidine is present [4]. Structural work reported a monomeric complex in solution and fast copper exchange attributed to a bis-GHK species [8], and potentiometric and spectroscopic studies described complexes with different stoichiometries, including binuclear species [9]. For a buyer the practical questions are whether the GHK-Cu used was supplied as a characterised copper complex, what the copper-to-peptide ratio is, and whether any free copper salt is present. Copper-to-peptide chemistry inside a three-component vial has not, as far as we know, been characterised in the published literature, which is exactly why the starting material should be documented.
6. Decide whether you need a blend at all
A blend is convenient, but the ratio is fixed. Laboratories studying a multi-component system usually run each component alone at matched concentrations, the full combination, and appropriate vehicle and copper controls. If your protocol needs different ratios or single-component arms, separate vials of BPC-157, TB-500 and GHK-Cu may suit better; our companion guides apply the same checklist to each. Peptide physical stability also depends on concentration, pH, ionic strength and other components in solution [10], so a mixture is a different system from three separate reagents.
7. Check the physical form, labelling and storage information
Research peptides and blends are usually supplied as a lyophilised (freeze-dried) powder in a sealed vial. Look for a label that states the product name, the composition, labelled content and lot number, and for storage requirements that come from the supplier’s batch documentation rather than improvised advice. Handling should follow the label, the batch documentation and your laboratory’s approved procedures; our article on copper chemistry and blend stability discusses the open questions. Be wary of any listing that gives usage instructions for people or animals, or uses cosmetic or skin-benefit language; that is a sign the material is not being sold for laboratory research.
8. Insist on lot numbers, then compare shipping and payment
A certificate describes only the batch it was run on. The lot number on any document should match the vial, and the test date and testing laboratory should be named. Do not assume documentation exists because a listing mentions purity: ask what is available for the batch before you order. Then check the practical side: where stock is held, which carrier is used and whether tracking is provided, whether totals are in Canadian dollars with taxes shown at checkout, which payment methods are accepted, and what happens if a parcel arrives damaged or incorrect. Domestic shipping from stock held in Canada avoids cross-border steps that can delay a parcel.
A short checklist
- The labelled amount of each component per vial is stated, and defined as net peptide or gross powder.
- The TB-500 component is identified by sequence (for example Ac-LKKTETQ) rather than by name only.
- Mass-spectrometry identity data cover all three components (BPC-157, TB-500 and GHK) for your batch.
- HPLC data say whether components were tested individually, as a blend, or both.
- The form of copper and the copper-to-GHK ratio are documented.
- Lot number, test date and testing laboratory appear on the document and match the vial.
- Price, shipping, carrier, tracking and returns are stated in Canadian dollars.
- The listing says laboratory research use only, with no instructions for people or animals and no health or cosmetic claims.
- Your institution’s approvals for the project are in place.
What the literature does not settle
Every study cited above examined a single substance, prepared and characterised by its authors; none examined a commercial three-component blend. They tell you what to ask a supplier, not what any particular vial contains. For a laboratory buyer the practical lesson is to record exactly which composition, which batch and which supplier each experiment used.
GLOW BLEND 70mg at PurixLab
GLOW BLEND 70mg: a research blend labelled as BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg per vial (70mg total), C$136 per vial (CAD, before tax), for laboratory research only. Product page: purixlab.com/product/glow-blend-70mg/.
Measured against the checklist above, note that the product page lists the labelled composition and refers to batch-specific documentation for handling and storage, but it does not currently display a certificate of analysis. If your project needs particular supporting documentation, such as the TB-500 sequence supplied, email [email protected] before ordering and tell us what you need; we will tell you what is available for the batch.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout). Current offers are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490-1498. PubMed 28035768 · doi:10.1002/dta.2152
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed 23084823 · doi:10.1016/j.chroma.2012.09.043
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027 · doi:10.1002/dta.1402
- Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 1981;199(3):649-56. PubMed 7340824 · PMC1163421 · doi:10.1042/bj1990649
- Roux S, Zékri E, Rousseau B, et al. Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches. J Pept Sci. 2008;14(3):354-9. PubMed 18035848 · doi:10.1002/psc.951
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-51. PubMed 20179146 · doi:10.1096/fj.09-142307
- D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. PubMed 25044089 · doi:10.1016/j.jpba.2014.06.012
- Hureau C, Eury H, Guillot R, et al. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry. 2011;17(36):10151-60. PubMed 21780203 · doi:10.1002/chem.201100751
- Conato C, Gavioli R, Guerrini R, et al. Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity. Biochim Biophys Acta. 2001;1526(2):199-210. PubMed 11325542 · doi:10.1016/s0304-4165(01)00127-1
- Zapadka KL, Becher FJ, Gomes Dos Santos AL, et al. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. PubMed 29147559 · PMC5665799 · doi:10.1098/rsfs.2017.0030